Last update Sept. 15, 2022

Pholcodine

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Pholcodine is a centrally acting opioid antitussive that has actions and uses similar to those of dextromethorphan. It has a mild sedative effect and no analgesic effect. May cause respiratory depression and hypotension like codeine. Does not cause addiction (Blanchard 2013). It is administered orally three or four times a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data do not allow a good prediction of the possible excretion in breast milk, because while its low binding to plasma proteins and long half-life would facilitate it, its very large volume of distribution would make it difficult.

The administration of pholcodine causes the production of anti-curare antibodies that persist for several years, with the risk of severe anaphylaxis during anesthesia. (Florvaag 2012, Guttormsen 2010, Harboe 2007)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Pholcodine in other languages or writings:

Group

Pholcodine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pholcodine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 88 %
Molecular weight 416 daltons
Protein Binding 21 - 23 %
VD 3.8 l/Kg
pKa 13.78 -
Tmax 1.3 hours
45 hours

References

  1. Blanchard E, Tunon de Lara M. [New insights into the role of pholcodine in the treatment of cough in 2013?]. Therapie. 2013 Mar-Apr;68(2):85-91. Abstract
  2. Florvaag E, Johansson SG. The Pholcodine Case. Cough Medicines, IgE-Sensitization, and Anaphylaxis: A Devious Connection. World Allergy Organ J. 2012 Jul;5(7):73-8. Abstract
  3. Guttormsen AB, Harboe T, Pater Gd, Florvaag E. [Anaphylaxis during anaesthesia]. Tidsskr Nor Laegeforen. 2010 Mar 11;130(5):503-6. Abstract
  4. Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy. 2007 Dec;62(12):1445-50. Abstract

Total visits

9,223

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM